{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060269","form_type":"8-K","ticker":"MYO","cik":"0001369290","company_name":"MYOMO, INC.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.775628+00:00","generated_at":"2026-06-08T14:14:02.098538+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Myomo Q3 record product revenue $5.0M, up 27% YoY; net loss narrows to $2.0M","bullets":["Total revenue $5.1M (+28% YoY); product revenue $5.0M (+27%) on 119 units (+37%).","Net loss $2.0M ($0.06/share) vs $2.8M loss ($0.40/share) in Q3 2022; adjusted EBITDA ($1.7M).","Received 156 MyoPro orders/authorizations (+20%); pipeline hits 1,046 candidates (+28%).","CMS reclassifies MyoPro as brace effective Jan 1, 2024; proposed fee rates $31,745 and $62,457.","First Medicare Part B rental payments received from all four DME MACs; six claims filed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060269","json":"https://secwatch.observer/filing/0000950170-23-060269.json","markdown":"https://secwatch.observer/filing/0000950170-23-060269.md","text":"https://secwatch.observer/filing/0000950170-23-060269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369290/000095017023060269/0000950170-23-060269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369290/000095017023060269/myo-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:14:02.098538+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f3ab3c68e54f70f6e930cc985568e24ee6f4f56","claim":"MYOMO, INC. reported the three and nine months ended September 30, 2023 results: revenue Total revenue was $5.1 million, net income Net loss for the third quarter of 2023 was $2.0 million, or $0.06 per share, EPS $0.06 per share.","evidence_excerpt":"--- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations Q3 total revenue of $5.1 million, up 28% over the prior year 156 MyoPro orders and insurance authorizations received, including the first payments for five Medicare Part B patients Conference call begins at 4:30","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369290/000095017023060269/0000950170-23-060269-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Revenue","value":"Total revenue was $5.1 million"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $2.0 million, or $0.06 per share"},{"label":"EPS","value":"$0.06 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}